← All trials
NCT03737461
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 18, 2019
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MontpellierLead sponsor
- University of MontpellierOverall official - principal investigator
- University of ParisCollaborator
- National University of IrelandCollaborator
- University of NantesCollaborator
- Campus Bio-Medico UniversityCollaborator
- University of ValladolidCollaborator
- University of RennesCollaborator
- University of MontpellierCollaborator
- University of LyonCollaborator
- University of NavarraCollaborator
- Institut de Terapia Regenerativa TissularCollaborator
- Univercell-Biosolutions S.A.SCollaborator
- Interdisziplinäres Zentrum Klinische Studien (IZKS)Collaborator
- European Clinical Research Infrastructure NetworkCollaborator
- CitospinCollaborator
- BG Klinikum Bergmannstrost, Halle, GermanyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.